US OptionsDetailed Quotes
BIIB241115P250000
- 0.00
- 0.000.00%
15min DelayClose Nov 14 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest250.00Strike Price0.00Turnover461.56%IV-51.62%PremiumNov 15, 2024Expiry Date85.11Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9742Delta0.0018Gamma1.93Leverage Ratio-1.2789Theta-0.0038Rho-1.88Eff Leverage0.0044Vega
Biogen Stock Discussion
Sign in to post a comment
Utilities: $NextEra Energy (NEE.US)$ $Duke Energy (DUK.US)$ $Southern (SO.US)$ $Consolidated Edison (ED.US)$ $Public Service Enterprise Group (PEG.US)$
Crypto: $Coinbase (COIN.US)$ $GEMINI GROUP GLOBAL CORP (GMNI.US)$ $Riot Platforms (RIOT.US)$
Financials: $JPMorgan (JPM.US)$ $Morgan Stanley (MS.US)$ $Wells Fargo & Co (WFC.US)$
Traditional Energy: $Exxon Mobil (XOM.US)$ $Chevron (CVX.US)$ $ConocoPhillips (COP.US)$
Biotechnology: $Amgen (AMGN.US)$ $Gilead Sciences (GILD.US)$ $ROCHE HOLDING AG (RHHBY.US)$ $Biogen (BIIB.US)$ $Regeneron Pharmaceuticals (REGN.US)$
...
Crypto: $Coinbase (COIN.US)$ $GEMINI GROUP GLOBAL CORP (GMNI.US)$ $Riot Platforms (RIOT.US)$
Financials: $JPMorgan (JPM.US)$ $Morgan Stanley (MS.US)$ $Wells Fargo & Co (WFC.US)$
Traditional Energy: $Exxon Mobil (XOM.US)$ $Chevron (CVX.US)$ $ConocoPhillips (COP.US)$
Biotechnology: $Amgen (AMGN.US)$ $Gilead Sciences (GILD.US)$ $ROCHE HOLDING AG (RHHBY.US)$ $Biogen (BIIB.US)$ $Regeneron Pharmaceuticals (REGN.US)$
...
7
Morning Movers
Gapping up
$Alphabet-A (GOOGL.US)$ stock rose 6.3% following third-quarter results that exceeded expectations, with a notable increase in advertising revenue, which alleviated concerns over competition from AI-driven search products.
$Biogen (BIIB.US)$ stock increased 1.2% after the biotech company raised its annual earnings forecast and reported third-quarter earnings that surpassed both top and bottom line expe...
Gapping up
$Alphabet-A (GOOGL.US)$ stock rose 6.3% following third-quarter results that exceeded expectations, with a notable increase in advertising revenue, which alleviated concerns over competition from AI-driven search products.
$Biogen (BIIB.US)$ stock increased 1.2% after the biotech company raised its annual earnings forecast and reported third-quarter earnings that surpassed both top and bottom line expe...
31
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Morning Movers
Gapping up
$Meta Platforms (META.US)$ stock rose 8.9% following stronger-than-expected second-quarter earnings and a positive future outlook.
$ConocoPhillips (COP.US)$ stock increased by 0.8% after reporting a second-quarter profit that surpassed estimates, aided by higher output and oil prices.
$Ferrari (RACE.US)$ stock climbed 3.3% as the company raised its full-year revenue and core earnings forecasts, having ex...
Gapping up
$Meta Platforms (META.US)$ stock rose 8.9% following stronger-than-expected second-quarter earnings and a positive future outlook.
$ConocoPhillips (COP.US)$ stock increased by 0.8% after reporting a second-quarter profit that surpassed estimates, aided by higher output and oil prices.
$Ferrari (RACE.US)$ stock climbed 3.3% as the company raised its full-year revenue and core earnings forecasts, having ex...
31
3
by Luzi Ann Santos | moomoo News
U.S. stocks advanced as $NVIDIA (NVDA.US)$, $Microsoft (MSFT.US)$, $Amazon (AMZN.US)$ and $Meta Platforms (META.US)$ rebounded after the latest U.S. economic data bolstered the case for the Federal Reserve to start cutting interest rates in the next few months.
The $S&P 500 Index (.SPX.US)$ rose 1.1% to close at 5459.10, while the tech-heavy $Nasdaq Composite Index (.IXIC.US)$ gained 1.03% to 17,...
U.S. stocks advanced as $NVIDIA (NVDA.US)$, $Microsoft (MSFT.US)$, $Amazon (AMZN.US)$ and $Meta Platforms (META.US)$ rebounded after the latest U.S. economic data bolstered the case for the Federal Reserve to start cutting interest rates in the next few months.
The $S&P 500 Index (.SPX.US)$ rose 1.1% to close at 5459.10, while the tech-heavy $Nasdaq Composite Index (.IXIC.US)$ gained 1.03% to 17,...
+1
98
14
Keep an eye on these recently announced M&As: 👀
$Merck & Co (MRK.US)$ to acquire EyeBio
$Biogen (BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson (JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals (RPHM.US)$
$Novartis AG (NVS.US)$ to acquire Mariana Oncology
What companies will be next? 🤔
$Merck & Co (MRK.US)$ to acquire EyeBio
$Biogen (BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson (JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals (RPHM.US)$
$Novartis AG (NVS.US)$ to acquire Mariana Oncology
What companies will be next? 🤔
6
$Biogen (BIIB.US)$ perhaps some puts on this 0.0
Keep an eye on these M&As: 👀
$Biogen (BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson (JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals (RPHM.US)$
$Harmony Biosciences (HRMY.US)$ acquired Epygenix Tx
What companies will be next? 🤔
$Biogen (BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson (JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals (RPHM.US)$
$Harmony Biosciences (HRMY.US)$ acquired Epygenix Tx
What companies will be next? 🤔
7
$Biogen (BIIB.US)$ 📣 Acquires Human Immunology Biosciences (HI-Bio)
⇨ Expands immunology portfolio 🧬
⇨ $1.15B upfront and up to $650M potential milestone payments 💰
⇨ Includes lead asset felzartamab, fully human anti-CD38 monoclonal antibody
» demonstrated clinical proof of concept in rare immune-mediated indications
» Planned Ph3 trial
⇨ Expands immunology portfolio 🧬
⇨ $1.15B upfront and up to $650M potential milestone payments 💰
⇨ Includes lead asset felzartamab, fully human anti-CD38 monoclonal antibody
» demonstrated clinical proof of concept in rare immune-mediated indications
» Planned Ph3 trial
4
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...
8
No comment yet
888huat888 : Ya what happens?
QMengColdJoke OP 888huat888 : eu approval for the Alzheimer medicine. Nay meaningless. I rushed to buy at 174.